Literature DB >> 781905

An investigation of the chest radiographs in a controlled trial of busulphan, cyclophosphamide, and a placebo after resection for carcinoma of the lung.

H Stott, R Stephens, W Fox, G Simon, D C Roy.   

Abstract

A standard series of radiographs of 588 patients allocated at random to treatment with busulphan (B patients), cyclophosphamide (C patients), or a placebo (P patients) for two years after surgery for bronchial carcinoma were viewed in three stages (following procedures which avoided bias) by an independent assessor, unaware of the allocated treatment of any patient, with a view to identifying pulmonary changes due to busulphan. Radiographic appearances consistent with busulphan lung were not reported in any of the 195 B patients (receiving a mean dosage of 464 mg of busulphan over 301 days) or of the 192 C patients but were present in one of the 201 patients receiving placebo.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 781905      PMCID: PMC470416          DOI: 10.1136/thx.31.3.265

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  22 in total

1.  DIFFUSE INTERSTITIAL PULMONARY FIBROSIS AFTER BUSULPHAN THERAPY.

Authors:  E LEAKE; W G SMITH
Journal:  Lancet       Date:  1963-08-31       Impact factor: 79.321

2.  Manifestations of acute leukemia in the parenchyma of the lung.

Authors:  D J NATHAN; M SANDERS
Journal:  N Engl J Med       Date:  1955-05-12       Impact factor: 91.245

3.  Interstitial pulmonary fibrosis following busulfan therapy.

Authors:  H OLINER; R SCHWARTZ; F RUBIO; W DAMESHEK
Journal:  Am J Med       Date:  1961-07       Impact factor: 4.965

4.  Myleran in chronic myeloid leukaemia; results of treatment.

Authors:  D A GALTON
Journal:  Lancet       Date:  1953-01-31       Impact factor: 79.321

5.  [Diffuse pneumopathy during chemotherapy with busulfan and bleomycin].

Authors:  L Jeanmart; J Klastersky; A Verhest; L Debusscher; P Potvliege; H Tagnon; M Tombroff
Journal:  J Belge Radiol       Date:  1972 Jul-Aug

6.  Interstitial pulmonary fibrosis, atypical epithelial changes and bronchiolar cell carcinoma following busulfan therapy.

Authors:  K W Min; F Györkey
Journal:  Cancer       Date:  1968-11       Impact factor: 6.860

7.  Busulphan lung.

Authors:  H J Woodliff; L R Finlay-Jones
Journal:  Med J Aust       Date:  1972-09-23       Impact factor: 7.738

8.  [Fatal pulmonary fibrosis, with cellular lesions of the lung and pancreas, attributed to busulfan].

Authors:  A Batzenschlager; F Oberling; M Guerbaoui; J M Vetter
Journal:  Arch Anat Pathol (Paris)       Date:  1972-09

9.  Lung function in patients receiving busulphan.

Authors:  W A Littler; C Ogilvie
Journal:  Br Med J       Date:  1970-11-28

10.  The effect of busulfan on human epithelia.

Authors:  L G Koss; M R Melamed; K Mayer
Journal:  Am J Clin Pathol       Date:  1965-10       Impact factor: 2.493

View more
  4 in total

1.  Acute respiratory failure during first cyclophosphamide infusion in a patient with systemic lupus erythematosus.

Authors:  P Schjelderup; T C El-Galaly; J B Frøkjær; T Ring
Journal:  Z Rheumatol       Date:  2014-12       Impact factor: 1.372

2.  The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study.

Authors:  Daniel M Green; Vikki G Nolan; Pamela J Goodman; John A Whitton; DeoKumar Srivastava; Wendy M Leisenring; Joseph P Neglia; Charles A Sklar; Sue C Kaste; Melissa M Hudson; Lisa R Diller; Marilyn Stovall; Sarah S Donaldson; Leslie L Robison
Journal:  Pediatr Blood Cancer       Date:  2013-08-12       Impact factor: 3.167

3.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

4.  5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus.

Authors:  H Stott; R J Stephens; W Fox; D C Roy
Journal:  Br J Cancer       Date:  1976-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.